Yong Zhang1, Yu'nan Zhu2, Erjiang Zhao3, Xiaolei He4, Lingdi Zhao1, Zibing Wang1, Xiaomin Fu1, Yalong Qi1, Baozhen Ma1, Yongping Song5, Quanli Gao1. 1. Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dong Ming Road, Zhengzhou 450003, China. 2. Department of Hematology, the 3rd People's Hospital of Zhengzhou, Zhengzhou, China. 3. Department of Biostatistics Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. 4. Department of Respiration, Shangqiu First People's Hospital, Zhengzhou, China. 5. Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dong Ming Road, Zhengzhou 450003, China.
Abstract
AIMS: Our study was conducted to explore the efficacy of autologous cytokine-induced killer (CIK) cells in patients with advanced malignant melanoma. Materials & Methods: Here we reviewed 113 stage IV malignant melanoma patients among which 68 patients received CIK cell immunotherapy alone, while 45 patients accepted CIK cell therapy combined with chemotherapy. Results: We found that the median survival time in CIK cell group was longer than the combined therapy group (21 vs 15 months, p = 0.07). In addition, serum hemoglobin level as well as monocyte proportion and lymphocyte count were associated with patients' survival time. CONCLUSIONS: These indicated that CIK cell immunotherapy might extend survival time in advanced malignant melanoma patients. Furthermore, serum hemoglobin level, monocyte proportion and lymphocyte count could be prognostic indicators for melanoma.
AIMS: Our study was conducted to explore the efficacy of autologous cytokine-induced killer (CIK) cells in patients with advanced malignant melanoma. Materials & Methods: Here we reviewed 113 stage IV malignant melanomapatients among which 68 patients received CIK cell immunotherapy alone, while 45 patients accepted CIK cell therapy combined with chemotherapy. Results: We found that the median survival time in CIK cell group was longer than the combined therapy group (21 vs 15 months, p = 0.07). In addition, serum hemoglobin level as well as monocyte proportion and lymphocyte count were associated with patients' survival time. CONCLUSIONS: These indicated that CIK cell immunotherapy might extend survival time in advanced malignant melanomapatients. Furthermore, serum hemoglobin level, monocyte proportion and lymphocyte count could be prognostic indicators for melanoma.
Authors: Lefu Huang; Guoliang Qiao; Michael A Morse; Xiaoli Wang; Xinna Zhou; Jiangping Wu; Amy Hobeika; Jun Ren; Herbert K Lyerly Journal: Oncol Lett Date: 2019-10-04 Impact factor: 2.967